SCOPUS 정보 검색 플랫폼

1
- 85058755274
- 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2019
- American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2019. Diabetes Care 42:suppl 1 (2019), S124–S138.
- (2019) Diabetes Care , vol.42 , pp. S124-S138

2
- 85039867196
- Diagnosis of diabetic kidney disease: state of the art and future perspective
- Persson, F, Rossing, P, Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl (2011) 8 (2018), 2–7.
- (2018) Kidney Int Suppl (2011) , vol.8 , pp. 2-7
- Persson, F.¹ Rossing, P.²

3
- 85016474227
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- Zoungas, S, Arima, H, Gerstein, HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5 (2017), 431–437.
- (2017) Lancet Diabetes Endocrinol , vol.5 , pp. 431-437
- Zoungas, S.¹ Arima, H.² Gerstein, H.C.³

4
- 70449360911
- Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial
- Zoungas, S, de Galan, BE, Ninomiya, T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32 (2009), 2068–2074.
- (2009) Diabetes Care , vol.32 , pp. 2068-2074
- Zoungas, S.¹ de Galan, B.E.² Ninomiya, T.³

5
- 85044754850
- Chronic kidney disease in diabetes
- Diabetes Canada Clinical Practice Guidelines Expert Commitee McFarlane, P, Cherney, D, Gilbert, RE, Senior, P, Chronic kidney disease in diabetes. Can J Diabetes 42:suppl 1 (2018), S201–SS09.
- (2018) Can J Diabetes , vol.42 , pp. S201-SS09
- McFarlane, P.¹ Cherney, D.² Gilbert, R.E.³ Senior, P.⁴

6
- 85065306608
- Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus
- Zelniker, TA, Wiviott, SD, Raz, I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139 (2019), 2022–2031.
- (2019) Circulation , vol.139 , pp. 2022-2031
- Zelniker, T.A.¹ Wiviott, S.D.² Raz, I.³

7
- 85044600598
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- Bethel, MA, Patel, RA, Merrill, P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6 (2018), 105–113.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 105-113
- Bethel, M.A.¹ Patel, R.A.² Merrill, P.³

8
- 85055101508
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- Hernandez, AF, Green, JB, Janmohamed, S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
- (2018) Lancet , vol.392 , pp. 1519-1529
- Hernandez, A.F.¹ Green, J.B.² Janmohamed, S.³

9
- 84978839381
- Liraglutide and cardiovascular outcomes in type 2 diabetes
- Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
- (2016) N Engl J Med , vol.375 , pp. 311-322
- Marso, S.P.¹ Daniels, G.H.² Brown-Frandsen, K.³

10
- 84994813253
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
- Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
- (2016) N Engl J Med , vol.375 , pp. 1834-1844
- Marso, S.P.¹ Bain, S.C.² Consoli, A.³

11
- 85028547742
- Liraglutide and renal outcomes in type 2 diabetes
- Mann, JFE, Orsted, DD, Brown-Frandsen, K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
- (2017) N Engl J Med , vol.377 , pp. 839-848
- Mann, J.F.E.¹ Orsted, D.D.² Brown-Frandsen, K.³

12
- 85055612603
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- Muskiet, MHA, Tonneijck, L, Huang, Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6 (2018), 859–869.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 859-869
- Muskiet, M.H.A.¹ Tonneijck, L.² Huang, Y.³

13
- 85068151338
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- published online June 10.
- Gerstein, HC, Colhoun, HM, Dagenais, GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 2019 published online June 10. http://dx.doi.org/10.1016/S0140-6736(19)31149-3.
- (2019) Lancet
- Gerstein, H.C.¹ Colhoun, H.M.² Dagenais, G.R.³

14
- 85048436169
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- Tuttle, KR, Lakshmanan, MC, Rayner, B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6 (2018), 605–617.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 605-617
- Tuttle, K.R.¹ Lakshmanan, M.C.² Rayner, B.³

15
- 85023614886
- Design and baseline characteristics of participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
- Gerstein, HC, Colhoun, HM, Dagenais, GR, et al. Design and baseline characteristics of participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 20 (2018), 42–49.
- (2018) Diabetes Obes Metab , vol.20 , pp. 42-49
- Gerstein, H.C.¹ Colhoun, H.M.² Dagenais, G.R.³

16
- 33747120659
- Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
- Levey, AS, Coresh, J, Greene, T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006), 247–254.
- (2006) Ann Intern Med , vol.145 , pp. 247-254
- Levey, A.S.¹ Coresh, J.² Greene, T.³

17
- 84859840957
- Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes
- Pogue, J, Devereaux, PJ, Thabane, L, Yusuf, S, Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One, 7, 2012, e34785.
- (2012) PLoS One , vol.7
- Pogue, J.¹ Devereaux, P.J.² Thabane, L.³ Yusuf, S.⁴

18
- 1542532754
- A proportional hazards model for the subdistribution of a competing risk
- Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
- (1999) J Am Stat Assoc , vol.94 , pp. 496-509
- Fine, J.P.¹ Gray, R.J.²

19
- 33845892180
- Change from baseline and analysis of covariance revisited
- Senn, S, Change from baseline and analysis of covariance revisited. Stat Med 25 (2006), 4334–4344.
- (2006) Stat Med , vol.25 , pp. 4334-4344
- Senn, S.¹

20
- 85041180129
- How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
- Inzucchi, SE, Zinman, B, Fitchett, D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
- (2018) Diabetes Care , vol.41 , pp. 356-363
- Inzucchi, S.E.¹ Zinman, B.² Fitchett, D.³

21
- 85030448557
- Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
- Holman, RR, Bethel, MA, Mentz, RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
- (2017) N Engl J Med , vol.377 , pp. 1228-1239
- Holman, R.R.¹ Bethel, M.A.² Mentz, R.J.³

22
- 84959363424
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
- Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
- (2016) Lancet , vol.387 , pp. 435-443
- Xie, X.¹ Atkins, E.² Lv, J.³

23
- 84922567942
- Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis
- Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A, Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
- (2015) JAMA , vol.313 , pp. 603-615
- Emdin, C.A.¹ Rahimi, K.² Neal, B.³ Callender, T.⁴ Perkovic, V.⁵ Patel, A.⁶

24
- 85038859145
- Effects of incretin-based therapies on renal function
- Tsimihodimos, V, Elisaf, M, Effects of incretin-based therapies on renal function. Eur J Pharmacol 818 (2018), 103–109.
- (2018) Eur J Pharmacol , vol.818 , pp. 103-109
- Tsimihodimos, V.¹ Elisaf, M.²

25
- 84945438826
- The glycocalyx–linking albuminuria with renal and cardiovascular disease
- Rabelink, TJ, de Zeeuw, D, The glycocalyx–linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol 11 (2015), 667–676.
- (2015) Nat Rev Nephrol , vol.11 , pp. 667-676
- Rabelink, T.J.¹ de Zeeuw, D.²

26
- 85048380312
- Dulaglutide and renal protection in type 2 diabetes
- Cherney, DZI, Verma, S, Parker, JD, Dulaglutide and renal protection in type 2 diabetes. Lancet Diabetes Endocrinol 6 (2018), 588–590.
- (2018) Lancet Diabetes Endocrinol , vol.6 , pp. 588-590
- Cherney, D.Z.I.¹ Verma, S.² Parker, J.D.³

27
- 85062789466
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
- Boye, KS, Riddle, MC, Gerstein, HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab 21 (2019), 1299–1304.
- (2019) Diabetes Obes Metab , vol.21 , pp. 1299-1304
- Boye, K.S.¹ Riddle, M.C.² Gerstein, H.C.³